Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elspeth M Beauchamp

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Vitamins and Hormones|March 7, 2012
A new era for an ancient drug: arsenic trioxide and Hedgehog signalingElspeth M Beauchamp, Aykut Uren
Blood|June 26, 2012
BH3 mimetics and multi-kinase inhibition in AMLElspeth M Beauchamp, Leonidas C Platanias
Plos One|May 12, 2011
YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasionSaid Rahim, Elspeth M Beauchamp, Yali Kong, et al.
Scientific Reports|September 8, 2019
Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastomaFrank Eckerdt, Jessica Clymer, Jonathan B Bell, et al.
Oncotarget|April 1, 2015
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinaseMarco Colamonici, Gavin Blyth, Diana Saleiro, et al.
Molecular Cancer Therapeutics|October 26, 2014
Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursorsElspeth M Beauchamp, Ewa M Kosciuczuk, Ruth Serrano, et al.
Oncotarget|September 17, 2015
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemiasDany A Curi, Elspeth M Beauchamp, Gavin T Blyth, et al.
Chemical Biology & Drug Design|July 2, 2019
Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screeningRama K Mishra, Matthew R Clutter, Gavin T Blyth, et al.
Blood Cancer Journal|March 4, 2021
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemiaBartholomew J Eisfelder, Caner Saygin, Joseph Wynne, et al.
Blood Neoplasia|June 24, 2025
Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AMLSara H Small, Ricardo E Perez, Elspeth M Beauchamp, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Vitamins and Hormones|March 7, 2012
A new era for an ancient drug: arsenic trioxide and Hedgehog signalingElspeth M Beauchamp, Aykut Uren
Blood|June 26, 2012
BH3 mimetics and multi-kinase inhibition in AMLElspeth M Beauchamp, Leonidas C Platanias
Plos One|May 12, 2011
YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasionSaid Rahim, Elspeth M Beauchamp, Yali Kong, et al.
Scientific Reports|September 8, 2019
Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastomaFrank Eckerdt, Jessica Clymer, Jonathan B Bell, et al.
Oncotarget|April 1, 2015
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinaseMarco Colamonici, Gavin Blyth, Diana Saleiro, et al.
Molecular Cancer Therapeutics|October 26, 2014
Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursorsElspeth M Beauchamp, Ewa M Kosciuczuk, Ruth Serrano, et al.
Oncotarget|September 17, 2015
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemiasDany A Curi, Elspeth M Beauchamp, Gavin T Blyth, et al.
Chemical Biology & Drug Design|July 2, 2019
Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screeningRama K Mishra, Matthew R Clutter, Gavin T Blyth, et al.
Blood Cancer Journal|March 4, 2021
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemiaBartholomew J Eisfelder, Caner Saygin, Joseph Wynne, et al.
Blood Neoplasia|June 24, 2025
Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AMLSara H Small, Ricardo E Perez, Elspeth M Beauchamp, et al.
Pageof 4